Gilead to Deliver More Remdesivir to Europe From Autumn

Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. (Mike Blake/Reuters)

Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. (Mike Blake/Reuters)

BERLIN—Gilead Sciences Inc plans to make more of its drug remdesivir available for Germany and Europe from autumn and will decide how much each country gets based on the rate of infection, the drugmakers Germany boss told a German magazine.

Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche the U.S. drugmaker can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December.

Bauer said she was in talks with the German government about increasing supply.

Gilead has faced criticism after the company allocated nearly all of its supply of remdesivir to the United States over the next three months, stirring concerns about availability elsewhere.

Germany has only a few hundred doses of remdesivir and has urged Gilead to increase production of the drug, which is the only treatment granted a conditional marketing authoRead More – Source